Treatment patterns, health care resource utilization and costs of rheumatoid arthritis patients in Italy: findings from a retrospective administrative database analysis

被引:12
|
作者
Fakhouri, Walid [1 ]
Lopez-Romero, Pedro [2 ]
Antonelli, Silvia [3 ]
Losi, Serena [4 ]
Rogai, Veronica [4 ]
Buda, Stefano [5 ]
Sangiorgi, Diego [5 ]
Perrone, Valentina [5 ]
Esposti, Luca Degli [5 ]
机构
[1] Eli Lilly & Co, Erl Wood, England
[2] Eli Lilly & Co, Madrid, Spain
[3] Eli Lilly Italy SpA, Rome, Italy
[4] Eli Lilly Italy SpA, Sesto Fiorentino, Italy
[5] CliCon Srl, Hlth Econ & Outcomes Res, Via Salara 36, I-48100 Ravenna, Italy
来源
OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS | 2018年 / 10卷
关键词
rheumatoid arthritis; treatment patterns; drug utilization; real-world data;
D O I
10.2147/OARRR.S164738
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: This study aimed to: 1) describe treatment patterns and drug utilization profile (in terms of therapeutic strategy used, switch, persistence and drug consumption variation) among adult patients affected by rheumatoid arthritis (RA), and 2) estimate the health care resource utilization and its associated direct cost for the management of RA patients. Methods: A retrospective cohort analysis, using administrative databases of six Local Health Units in Italy, was performed. All adult patients with a confirmed diagnosis of RA between January 1, 2010 and December 31, 2014 were enrolled. The date of the first RA diagnosis according to the study criteria during the study period represented the index date (ID) for each patient. Patients enrolled were observed from the ID for at least 12 months (follow-up period), and their clinical characteristics were investigated for 12 months prior to the ID. Results: A total of 10,401 patients with a confirmed RA diagnosis were included. Mean age was 63.0 years and 25% were male; 67% of patients were untreated at ID. During the followup period, 67.8% of patients treated with biologic agents were persistent with initial therapy, compared to 45.7% for patients on conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), while 11% of patients treated with biologic agents switched during the follow-up period, compared to 17.6% of csDMARDs-treated ones. At the end of the follow-up period, 14.7% of all patients in the analysis had an increase and 12.6% of them had a decrease in their initial drug consumption. The mean cost per RA patient was (sic)3,743. Conclusion: Our study showed that there is still much that needs to be learned about the prescription of csDMARDs and biologics to RA patients in Italy and to identify areas for future research. The knowledge of RA management in a real-life clinical setting could offer an opportunity to improve the management of RA in Italy.
引用
收藏
页码:103 / 111
页数:9
相关论文
共 50 条
  • [11] CLAIMS DATABASE ANALYSIS OF ADHERENCE TO ADALIMUMAB THERAPY AND HEALTH CARE COSTS FOR PATIENTS WITH RHEUMATOID ARTHRITIS
    Liu, Y.
    Tundia, N.
    Skup, M.
    Ayyagari, R.
    Du, E. X.
    Chao, J.
    Mulani, P.
    Bao, Y.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 944 - 944
  • [12] TREATMENT PATTERNS, RESOURCE UTILIZATION AND COSTS IN MUSCULAR DYSTROPHY PATIENTS: ANALYSIS USING ADMINISTRATIVE CLAIMS DATA
    Stott-Miller, M.
    Vlahiotis, A.
    Palmer, L. A.
    VALUE IN HEALTH, 2015, 18 (07) : A764 - A765
  • [13] Treatment patterns of COPD patients in France: A retrospective analysis of an administrative primary care healthcare database
    Jakubanis, Rafal
    Meeraus, Wilhelmine
    Wood, Robert
    Holbrook, Tim
    Despres, Johanna
    Bizouard, Geoffray
    Landis, Sarah
    Punekar, Yogesh
    Ismaila, Afisi
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [14] RESOURCE UTILIZATION AND HEALTH CARE COSTS ASSOCIATED WITH DIVERTICULAR DISEASE: RESULTS FROM A RETROSPECTIVE CLAIMS DATABASE ANALYSIS IN THE UNITED STATES
    Yen, L.
    Davis, K.
    Longstreth, G.
    Streck, P.
    Hodgkins, P.
    VALUE IN HEALTH, 2011, 14 (03) : A183 - A183
  • [15] Treatment patterns and health care resource utilization associated with dalfampridine extended release in multiple sclerosis: a retrospective claims database analysis
    Guo, Amy
    Grabner, Michael
    Palli, Swetha Rao
    Elder, Jessica
    Sidovar, Matthew
    Aupperle, Peter
    Krieger, Stephen
    CLINICOECONOMICS AND OUTCOMES RESEARCH, 2016, 8 : 177 - 186
  • [16] HEALTH CARE RESOURCE USES AND COSTS IN COLOMBIAN EARLY RHEUMATOID ARTHRITIS PATIENTS
    Rojas, Diaz J. A.
    Quintana, G.
    Aristizabal, F.
    Brown, P.
    VALUE IN HEALTH, 2017, 20 (05) : A147 - A148
  • [17] Exploring drug utilization patterns, healthcare resource utilization, and epidemiology of rheumatoid arthritis in Colombia: a retrospective claims database study
    Fernandez-avila, Daniel G.
    Betancur, Monica
    Kronfly, Amira
    Jauregui, Edwin
    BMC RHEUMATOLOGY, 2025, 9 (01)
  • [18] Treatment patterns and health care resource utilization among Japanese patients with ankylosing spondylitis: A hospital claims database analysis
    Tomita, Tetsuya
    Sato, Masayo
    Esterberg, Elizabeth
    Parikh, Rohan C.
    Hagimori, Kohei
    Nakajo, Ko
    MODERN RHEUMATOLOGY, 2021, 31 (02) : 431 - 441
  • [19] Impact of Switching From an Initial Tumor Necrosis Factor Inhibitor on Health Care Resource Utilization and Costs Among Patients With Rheumatoid Arthritis
    Baser, Onur
    Ganguli, Arijit
    Roy, Sanjoy
    Xie, Lin
    Cifaldi, Mary
    CLINICAL THERAPEUTICS, 2015, 37 (07) : 1454 - 1465
  • [20] Ixekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study
    Danve, Abhijeet
    Vadhariya, Aisha
    Lisse, Jeffrey
    Cholayil, Arjun
    Bansal, Neha
    Bello, Natalia
    Bakewell, Catherine
    RHEUMATOLOGY AND THERAPY, 2024, 11 (05) : 1333 - 1345